Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
4,803 total articles
Nano Nuclear Energy (NNE) has retraced roughly 60% from its 2025 highs and is showing renewed volume and bullish momentum signals. With a $1.17B market cap, net cash-like enterprise value, and a near-term cash burn profile that’s been disclosed, this trade idea outlines a mid-term (45 trading days) long with a defined entry, stop and target to capt…
Smartphone unit competition and component cost pressure are capping margins for Xiaomi today. That said, the company’s heavy bets on consumer robotics, home automation, and agentic AI could be a multi-year re-rate catalyst if execution matches ambition. This trade idea sizes a long position to capture upside from product cycle stabilization and AI/…
NewLake Capital Partners yields roughly 12% today yet shows tangible AFFO coverage, $106.3M of liquidity and a concentrated but cash-generating cannabis real estate portfolio. This trade idea lays out an actionable long with precise entry, stop and target, plus the catalysts and risks that matter.
Apple's hardware-software stack and massive installed base make it a pragmatic infrastructure beneficiary of local AI adoption. With a $3.8T market cap, $123.3B in free cash flow, and conservative AI spend positioning, Apple is set to monetize on-device models, chips, and services. This trade idea proposes a long entry at $258.93 with a $245 stop a…
Nvidia is trading like momentum faded, but fundamentals and strategic moves (including a $2B strategic investment in Marvell) point to outsized upside. This trade idea proposes a disciplined long entry at $180.00 with a $235.00 target and a $168.00 stop, sized for a long-term horizon (180 trading days).
TKMS has seen upward estimate revisions from sell-side analysts while the market has pushed shares lower. That divergence creates a risk-defined buying opportunity for disciplined traders. This trade plan lays out entry at $12.25, a conservative stop at $10.50, and staged targets at $15.00 and $18.00 over a 180 trading-day horizon.
UnitedHealth (UNH) just received a material near-term earnings tailwind from CMS Medicare Advantage rate increases. The stock has started to reprice, momentum indicators are bullish, and valuation still has room to expand versus recent troughs. This trade idea outlines an entry at $305.93, a stop at $292.00 and a $360 target on a mid-term (45 tradi…
Rivian is transitioning from a pure-play hardware EV maker to a software-defined vehicle platform with meaningful upside if execution on R2, Uber autonomous commitments, and software/services monetization accelerate. Valuation at ~3.4x sales already prices some growth; the trade targets a mid-term re-rating while acknowledging cash burn and executi…
GLD has pulled back from the January peak and is trading near the mid-point of its recent range. With easing Fed expectations, central bank demand and geopolitical shocks keeping safe-haven flows alive, I recommend a tactical long in GLD with defined entry, stop and target for a 180-trading-day trade.
Structure Therapeutics (GPCR) reported Phase 2 results showing placebo-adjusted weight loss in the mid-teens at 44 weeks for aleniglipron, an oral GLP-1 receptor agonist. The data position the drug as best-in-class among oral options and competitive with injectables. With a market cap near $3.8B, meaningful cash on the balance sheet and a planned P…
Samsung's Q1 profit guide came in meaningfully ahead of consensus. That upside, combined with improving semiconductor end-markets and structural memory demand normalization, creates a clear tactical buying opportunity in the ADR SSNLF. We provide an entry at $70.00, a stop at $62.00 and a target at $85.00 with a mid-to-long-term horizon and balance…
AtaiBeckley (ATAI) just cleared two practical barriers: peer-reviewed Phase 2a/2b data showing rapid, durable antidepressant effects for BPL-003 and an FDA End-of-Phase 2 outcome that keeps a Phase 3 start on track for Q2 2026. With a cash runway through early 2029 and a market cap near $1.37B, this name offers an asymmetric swing trade: entry arou…
Fiserv is a deeply discounted payments-and-fintech platform trading at single-digit P/E and attractive cash flow metrics. New CEO Michael P. Lyons is consolidating the business under the 'One Fiserv' playbook, prioritizing AI integration and new settlement rails. This trade idea is a tactical long: enter near $56.67, protect at $50.00, and target $…
Palantir plunged today but DevCon5 reinforced the company’s product-led AI story. With Foundry AI adoption accelerating and government contracts providing a base, this trade buys the post-event reset at $140 with a stop at $120 and a target of $195 over the next 45 trading days.
Rocket Lab presents a buy-the-dip opportunity after recent headlines highlighted both premium valuation and program delays. With a $37 billion market cap and an underappreciated government and commercial backlog, a disciplined long with clear stops captures asymmetric upside while limiting downside from execution risk.
Intercontinental Exchange (ICE) combines predictable marketplace cash flows, a durable mortgage-technology growth runway and favorable rate dynamics. Technical momentum and improving product integrations make a mid-term long trade to challenge the $189.35 52-week high attractive. Entry $167.05, initial target $190.00, stop $156.00 - mid-term (45 tr…
Zscaler (ZS) is trading near $140 after a sector-wide repricing. The company sits at the intersection of zero-trust security and a rising need to protect AI infrastructure. With a market cap of roughly $22.4B, solid free cash flow ($947M trailing), improving technical breadth and elevated short interest, this is an actionable long trade to buy the …
Palantir is undergoing a re-rating as its Foundry AI adoption accelerates in commercial markets while the government business remains a steady revenue anchor. Recent weakness creates a tactical entry for disciplined buyers. This trade idea lays out an actionable plan, valuation context, catalysts, and the risks that would change our view.
Globant (GLOB) trades like a company in distress at $45.61 while its fundamentals and product roadmap suggest a reasonable rebound. Sub-$2B market cap, a P/B near 1.0 and recent technical signals support a swing trade with asymmetric reward-to-risk. Entry $45.61, stop $41.00, target $60.00 - mid-term (45 trading days) setup with targeted catalysts …
Sysco's $29.1B purchase of Jetro Restaurant Depot materially reshapes its scale and margin profile. The combination pushes pro forma revenue toward ~$100B and management projects ~45% EBITDA uplift and $250M of annual cost synergies. The market sold off on deal risk and leverage worries; that creates a tactical long opportunity at today's ~$75.19 q…
Eli Lilly is priced for high growth but the stock still offers an asymmetric risk/reward: new oral GLP-1 approval and a dominant pipeline combined with strong cash generation and recent strategic M&A give buyers a clear entry for a long-term position. This trade idea lays out the rationale, exact entry/stop/target, catalysts, and the scenarios that…
Apple's recent pullback on reports of engineering challenges for a foldable iPhone looks like an overreaction. Strong cash flow, conservative AI strategy, and a huge installed base mean a September launch expectation can be missed without derailing the business. This trade idea lays out an entry at $258.00, a stop at $245.00, and a target of $285.0…
Mesoblast’s FDA clearance to proceed directly to a registrational trial of Ryoncil (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD) is a material derisking event for a company already showing commercial traction with its launched product. With Q1 net sales of $30.3M and H1 FY2026 product revenue of $48.7M producing an unusually high gross …
Dow rallied hard in March as petrochemical dislocations lifted U.S. players. After a rapid run and profit-taking, shares are digesting gains around $37.8 with valuation and dividend yield that support a tactical long. This note lays out an actionable swing trade: entry, stop, targets, catalysts and the scenarios that would make us change course.
Microsoft is the safest, biggest way to play the AI buildout. Strong free cash flow, high ROE, ongoing enterprise AI rollouts, and recent partnership wins underpin a trade that targets a re-rating as Azure monetizes agentic AI. Entry $377.00, stop $355.00, target $430.00 — position trade (45 trading days).
